Literature DB >> 26352243

Abdominal aortic aneurysm: novel mechanisms and therapies.

Frank M Davis1, Debra L Rateri, Alan Daugherty.   

Abstract

PURPOSE OF REVIEW: Abdominal aortic aneurysm (AAA) is a pathological condition of permanent dilation that portends the potentially fatal consequence of aortic rupture. This review emphasizes recent advances in mechanistic insight into aneurysm pathogenesis and potential pharmacologic therapies that are on the horizon for AAAs. RECENT
FINDINGS: An increasing body of evidence demonstrates that genetic factors, including 3p12.3, DAB2IP, LDLr, LRP1, matrix metalloproteinase (MMP)-3, TGFBR2, and SORT1 loci, are associated with AAA development. Current human studies and animal models have shown that many leukocytes and inflammatory mediators, such as IL-1, IL-17, TGF-β, and angiotensin II, are involved in the pathogenesis of AAAs. Leukocytic infiltration into aortic media leads to smooth muscle cell depletion, generation of reactive oxygen species, and extracellular matrix fragmentation. Preclinical investigations into pharmacological therapies for AAAs have provided intriguing insight into the roles of microRNAs in regulating many pathological pathways in AAA development. Several large clinical trials are ongoing, seeking to translate preclinical findings into therapeutic options.
SUMMARY: Recent studies have identified many potential mechanisms involved in AAA pathogenesis that provide insight into the development of a medical treatment for this disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26352243      PMCID: PMC4624089          DOI: 10.1097/HCO.0000000000000216

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  75 in total

Review 1.  Abdominal aortic aneurysm: pathogenesis and implications for management.

Authors:  Jonathan Golledge; Juanita Muller; Alan Daugherty; Paul Norman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-09-14       Impact factor: 8.311

2.  Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development.

Authors:  Lars Maegdefessel; Junya Azuma; Ryuji Toh; Denis R Merk; Alicia Deng; Jocelyn T Chin; Uwe Raaz; Anke M Schoelmerich; Azad Raiesdana; Nicholas J Leeper; Michael V McConnell; Ronald L Dalman; Joshua M Spin; Philip S Tsao
Journal:  J Clin Invest       Date:  2012-01-24       Impact factor: 14.808

Review 3.  Leukotriene modifiers as potential therapeutics for cardiovascular disease.

Authors:  Colin D Funk
Journal:  Nat Rev Drug Discov       Date:  2005-08       Impact factor: 84.694

4.  Association of osteoprotegerin with human abdominal aortic aneurysm progression.

Authors:  Corey S Moran; Moira McCann; Mirko Karan; Paul Norman; Natkunam Ketheesan; Jonathan Golledge
Journal:  Circulation       Date:  2005-06-06       Impact factor: 29.690

5.  Inhibited aortic aneurysm formation in BLT1-deficient mice.

Authors:  Neil Ahluwalia; Alexander Y Lin; Andrew M Tager; Ivy E Pruitt; Thomas J T Anderson; Fjoralba Kristo; Dongxiao Shen; Anna R Cruz; Masanori Aikawa; Andrew D Luster; Robert E Gerszten
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

6.  The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm.

Authors:  Lei Zhao; Michael P W Moos; Rolf Gräbner; Frédérique Pédrono; Jinjin Fan; Brigitte Kaiser; Nicole John; Sandra Schmidt; Rainer Spanbroek; Katharina Lötzer; Li Huang; Jisong Cui; Daniel J Rader; Jilly F Evans; Andreas J R Habenicht; Colin D Funk
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

Review 7.  Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms.

Authors:  Nikolaos P Kadoglou; Christos D Liapis
Journal:  Curr Med Res Opin       Date:  2004-04       Impact factor: 2.580

8.  Angiotensin II-induced abdominal aortic aneurysm occurs independently of the 5-lipoxygenase pathway in apolipoprotein E-deficient mice.

Authors:  Richard Yang Cao; Michael A Adams; Andreas J Habenicht; Colin D Funk
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-03-24       Impact factor: 3.072

9.  Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan.

Authors:  Yoshikazu Fujiwara; Suguru Shiraya; Takashi Miyake; Satoshi Yamakawa; Motokuni Aoki; Hirofumi Makino; Motonobu Nishimura; Ryuichi Morishita
Journal:  Int J Mol Med       Date:  2008-12       Impact factor: 4.101

10.  Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation.

Authors:  Elena Kaschina; Felix Schrader; Manuela Sommerfeld; Ulrich Rudolf Kemnitz; Aleksandra Grzesiak; Maxim Krikov; Thomas Unger
Journal:  J Hypertens       Date:  2008-12       Impact factor: 4.844

View more
  49 in total

1.  Chemokine (C-X-C motif) receptor 2 blockade by SB265610 inhibited angiotensin II-induced abdominal aortic aneurysm in Apo E-/- mice.

Authors:  Hao Nie; Hong-Xia Wang; Cui Tian; Hua-Liang Ren; Fang-Da Li; Chao-Yu Wang; Hui-Hua Li; Yue-Hong Zheng
Journal:  Heart Vessels       Date:  2018-12-07       Impact factor: 2.037

2.  Mechanisms underlying the inhibitory effects of probucol on elastase-induced abdominal aortic aneurysm in mice.

Authors:  Cong Chen; Yunxia Wang; Yini Cao; Qinyu Wang; Gulinigaer Anwaier; Qingyi Zhang; Rong Qi
Journal:  Br J Pharmacol       Date:  2019-11-03       Impact factor: 8.739

3.  Vascular ADAM17 (a Disintegrin and Metalloproteinase Domain 17) Is Required for Angiotensin II/β-Aminopropionitrile-Induced Abdominal Aortic Aneurysm.

Authors:  Tatsuo Kawai; Takehiko Takayanagi; Steven J Forrester; Kyle J Preston; Takashi Obama; Toshiyuki Tsuji; Tomonori Kobayashi; Michael J Boyer; Hannah A Cooper; Hang Fai Kwok; Tomoki Hashimoto; Rosario Scalia; Victor Rizzo; Satoru Eguchi
Journal:  Hypertension       Date:  2017-09-25       Impact factor: 10.190

4.  Alterations in phenotype and gene expression of adult human aneurysmal smooth muscle cells by exogenous nitric oxide.

Authors:  Kurt Farrell; Phillip Simmers; Gautam Mahajan; Ludovic Boytard; Andrew Camardo; Jyotsna Joshi; Anand Ramamurthi; Florence Pinet; Chandrasekhar R Kothapalli
Journal:  Exp Cell Res       Date:  2019-08-29       Impact factor: 3.905

5.  The pathogenesis shared between abdominal aortic aneurysms and intracranial aneurysms: a microarray analysis.

Authors:  Wen Wang; Hao Li; Zheng Zhao; Haoyuan Wang; Dong Zhang; Yan Zhang; Qing Lan; Jiangfei Wang; Yong Cao; Jizong Zhao
Journal:  Neurosurg Rev       Date:  2017-10-14       Impact factor: 3.042

6.  Understanding AAA Pathobiology: A GWAS Leads the Way.

Authors:  Daniel I Chasman; Patrick R Lawler
Journal:  Circ Res       Date:  2017-01-20       Impact factor: 17.367

Review 7.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

8.  New Mouse Model of Abdominal Aortic Aneurysm: Put Out to Expand.

Authors:  Stoyan N Angelov; Jay Zhu; David A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11       Impact factor: 8.311

Review 9.  Abdominal Aortic Aneurysm: Evolving Controversies and Uncertainties.

Authors:  Davide Carino; Timur P Sarac; Bulat A Ziganshin; John A Elefteriades
Journal:  Int J Angiol       Date:  2018-05-29

10.  Inhibitory effects of cycloastragenol on abdominal aortic aneurysm and its related mechanisms.

Authors:  Yunxia Wang; Cong Chen; Qinyu Wang; Yini Cao; Lu Xu; Rong Qi
Journal:  Br J Pharmacol       Date:  2018-12-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.